Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Emyria Limited (EMD.AX)
AUD0.04
+0.00 (+5.13%)
AU ASX Healthcare Medical - Healthcare Information Services
Address
D2, 661 Newcastle Street 6007
Leederville, WA, AU
Leederville, WA, AU
CEO
Gregory Hutchinson
Website
emyria.com
IPO
2020-02-11
ISIN AU0000073645
Description
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.04
+0.00 (+5.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.03
Float Shares
424.86M
Free Float %
74.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.89% | +22.50% | -2.00% | -7.55% | -14.04% | -16.95% | +81.48% | -62.42% | -76.40% | -65.01% | -65.01% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.04
Quality scores
Altman Z-Score
6.62
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%-36.7% Q4'25: +32.1% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+78.1% ★ Q4'25: +89.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-182.4% Q4'25: -145.2% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-178.8% Q4'25: -174.0% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-106.2% Q4'25: -376.8% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+25.0% Q4'25: +103.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.26× Q4'25: -0.12× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.01M
est: 100.0K (+913.5%)
|
1.98M
est: 1.10M (+79.6%)
|
1.82M
est: 2.60M (-29.9%)
|
1.59M
est: 4.00M (-60.2%)
|
2.20M
est: 6.10M (-63.9%)
|
1.39M
est: 4.10M (-66.0%)
|
9.70M
9.70M – 9.70M
+136.6% YoY
|
19.40M
19.40M – 19.40M
+100.0% YoY
|
32.20M
32.20M – 32.20M
+66.0% YoY
|
| EBITDA |
-4.80M
est: -100.0K (-4,695.0%)
|
-4.49M
est: -1.10M (-308.6%)
|
-8.03M
est: -2.60M (-208.8%)
|
-6.69M
est: -4.00M (-67.3%)
|
-13.03M
est: -6.10M (-113.7%)
|
-2.39M
est: -4.10M (+41.6%)
|
-9.70M
-9.70M – -9.70M
-136.6% YoY
|
-19.40M
-19.40M – -19.40M
-100.0% YoY
|
-32.20M
-32.20M – -32.20M
-66.0% YoY
|
| EBIT |
-5.18M
est: -100.0K (-5,078.5%)
|
-4.84M
est: -1.10M (-339.9%)
|
-8.42M
est: -2.60M (-223.8%)
|
-7.09M
est: -4.00M (-77.3%)
|
-13.73M
est: -6.10M (-125.1%)
|
-2.49M
est: -4.10M (+39.2%)
|
-9.70M
-9.70M – -9.70M
-136.6% YoY
|
-19.40M
-19.40M – -19.40M
-100.0% YoY
|
-32.20M
-32.20M – -32.20M
-66.0% YoY
|
| Net Income |
-5.24M
|
-4.91M
|
-7.33M
|
-5.13M
|
-11.46M
|
-3.14M
est: -2.69M (-16.8%)
|
-3.59M
-3.59M – -3.59M
-33.3% YoY
|
-2.69M
-2.69M – -2.69M
+25.0% YoY
|
2.69M
2.69M – 2.69M
+200.0% YoY
|
| SGA |
1.34M
est: 106.0K (+1,163.5%)
|
1.51M
est: 1.17M (+29.3%)
|
1.92M
est: 2.76M (-30.5%)
|
2.00M
est: 4.24M (-52.9%)
|
1.98M
est: 6.46M (-69.4%)
|
1.86M
est: 4.34M (-57.2%)
|
10.28M
10.28M – 10.28M
+136.6% YoY
|
20.56M
20.56M – 20.56M
+100.0% YoY
|
34.12M
34.12M – 34.12M
+66.0% YoY
|
| EPS |
-0.03
|
-0.02
|
-0.03
|
-0.02
|
-0.03
|
-0.01
est: -0.01 (-16.7%)
|
-0.01
-0.01 – -0.01
-33.3% YoY
|
-0.01
-0.01 – -0.01
+25.0% YoY
|
0.01
0.01 – 0.01
+200.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.60M
OE per share TTM
-0.01
Owner's Yield
-13.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
64.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-415.6K
Shares Outstanding
572.76M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alistair Vickery | Executive Medical Director & Director | 485.4K | — |
| Michael Winlo | Chief Scientific Officer & Executive Director | 349.8K | — |
| Gregory Hutchinson | Executive Chairman | 289.3K | male |
| Tracie Ernenwein | Head of Research & Drug Development | — | female |
| Mary-Ann Rennie | Head of Corporate Operations | — | — |
| Joseph Daniel Ohayon Intl Bus. | Chief Financial Officer | — | male |
| Susan Patricia Park ACSA AGIA | Company Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EMD.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
